Sittner & Nelson LLC Has $2.02 Million Holdings in Amgen Inc. $AMGN

Sittner & Nelson LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,246 shares of the medical research company’s stock after selling 183 shares during the quarter. Amgen accounts for approximately 0.8% of Sittner & Nelson LLC’s investment portfolio, making the stock its 24th largest position. Sittner & Nelson LLC’s holdings in Amgen were worth $2,023,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen during the 1st quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC lifted its stake in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after purchasing an additional 85 shares during the last quarter. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at $27,000. Activest Wealth Management increased its stake in shares of Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 103 shares during the last quarter. Finally, Quaker Wealth Management LLC raised its holdings in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after buying an additional 240 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on AMGN. UBS Group decreased their target price on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. DZ Bank lifted their price target on shares of Amgen from $335.00 to $364.00 in a report on Monday. Piper Sandler reissued an “overweight” rating on shares of Amgen in a research note on Wednesday, November 5th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Bank of America upped their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Eight research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $312.00.

Amgen Price Performance

AMGN stock opened at $336.00 on Friday. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The company’s 50-day moving average is $293.85 and its 200-day moving average is $290.01. The stock has a market capitalization of $180.93 billion, a PE ratio of 27.47, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $345.84.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is 73.57%.

Insider Buying and Selling at Amgen

In other news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 9,036 shares of company stock valued at $2,992,594. Corporate insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.